Back to results

Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A (Canopy-A)

Primary Purpose

Non-Small Cell Lung Cancer

Status

Terminated

Phase

Phase 3

Locations

International

Study Type

Interventional

Intervention

Canakinumab

Placebo

About this trial

This is an interventional treatment trial for Non-Small Cell Lung Cancer focused on measuring Non-Small Cell Lung Cancer, NSCLC, ACZ885, canakinumab, adjuvant, AJCC/UICC v. 8 stages II-IIIA and IIIB (T>5cm N2)

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Have completely resected (R0) NSCLC AJCC/UICC v. 8 stage IIA-IIIA and IIIB (N2 disease only) OR have NSCLC Stage IIA-IIIA, IIIB (N2 disease only) and are candidates for complete resection surgery
Cisplatin-based chemotherapy is mandatory for all subjects (Exception: In subjects with stage IIA disease with no nodal involvement, cisplatin-based chemotherapy can be administered if recommended by the treating physician). When required, a minimum of two cycles of cisplatin-based chemotherapy is mandatory, after which additional therapies can be given based upon local clinical practice and/or guidelines. Typically, chemotherapy is initiated within 60 days of surgery.
Must have recovered from all toxicities related to prior systemic therapy to grade ≤ 1 (CTCAE v 4.03). Exception to this criterion: subjects with any grade of alopecia and grade 2 or less neuropathy are allowed to enter the study
Have ECOG performance status (PS) of 0 or 1

Exclusion Criteria:

Have unresectable or metastatic disease, positive microscopic margins on the pathology report, and/or gross disease remaining at the time of surgery
Have received any neoadjuvant therapy
Presence or history of a malignant disease, other than the resected NSCLC, that has been diagnosed and/or required therapy within the past 3 years Exceptions to this exclusion include the following: completely resected basal cell and squamous cell skin cancers, completely resected carcinoma in situ of any type and hormonal maintenance for breast and prostate cancer > 3 years.
Have a history of current diagnosis of cardiac disease
Have uncontrolled diabetes
Have known active or recurrent hepatic disorder including cirrhosis, hepatitis B and C (positive or indeterminate central laboratory results)
Subjects must be evaluated for tuberculosis as per local treatment guidelines or clinical practice. Subjects with active tuberculosis are not eligible.
Have suspected or proven immunocompromised state as described in the protocol
Had Live and attenuated vaccination within 3 months prior to first dose of study drug (e.g. MMR, Yellow Fever, Rotavirus, Smallpox, etc.).

Other inclusion/exclusion criteria may apply

Sites / Locations

Highlands Oncology Group
Cancer and Blood Specialty Clinic
University of California at Los Angeles
VA Palo Alto Health Care System CRLX030A2301
Sansum Clinic
Rocky Mountain Cancer Centers Denver-Mdtn(Bone&MarrowTransp)
Florida Cancer Specialists
Advanced Medical Specialties Drug Ship - 2
Florida Cancer Affiliates of Ocala
Florida Cancer Specialists North
Florida Cancer Specialists Panhandle
Florida Cancer Specialists
Rush University Medical Center CLDT600AUS06
Cancer Center of Kansas Dept.ofCancerCtr.ofKansas
VA Nebraska-Western Iowa Health Care System
Louis Stokes Cleveland Department of Veterans Affairs MC
Oncology Associates of Oregon, PC
Chattanooga Oncology and Hematology Associates PC Chattanooga Oncology
Sarah Cannon Research Institute
VA North Texas Health Care System
Texas Oncology MamieMcFaddenWardCtr
Virginia Cancer Specialists Fairfax Northern Virginia
Oncology and Hematology Associates of Southwest Virginia Inc
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site
Novartis Investigative Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

canakinumab

Placebo

Arm Description

Participants will receive canakinumab for 18 cycles (approximately 54 weeks).

Participants will receive canakinumab placebo for 18 cycles (approximately 54 weeks).

Outcomes

Primary Outcome Measures

Disease free survival (DFS) by local investigator

DFS is the time from the date of randomization to the date of the first documented NSCLC disease recurrence as assessed by local investigator radiologically or death due to any cause.

Secondary Outcome Measures

Overall Survival (OS)

Overall Survival (OS) is the time from the date of randomization to the date of death due to any cause.

Disease free survival (DFS) by local investigator in PD-L1 subgroups

DFS is the time from the date of randomization to the date of the first documented NSCLC disease recurrence as assessed by local investigator radiologically or death due to any cause. DFS analysis will be performed by programmed cell death-ligand 1 (PD-L1) status (positive, negative) where a positive status is defined as having ≥ 1% expression and a negative status is defined as having < 1% expression.

Disease free survival (DFS) by local investigator in CD8 subgroups

DFS is the time from the date of randomization to the date of the first documented NSCLC disease recurrence as assessed by local investigator radiologically or death due to any cause. DFS analysis will be performed by CD8 subgroups with the median and quartiles of baseline CD8 expression as cut-offs.

Overall Survival (OS) by local investigator in PD-L1 subgroups

Overall Survival (OS) is the time from the date of randomization to the date of death due to any cause. OS analysis will be performed by programmed cell death-ligand 1 (PD-L1) status (positive, negative) where a positive status is defined as having ≥ 1% expression and a negative status is defined as having < 1% expression.

Overall Survival (OS) by local investigator in CD8 subgroups

Overall Survival (OS) is the time from the date of randomization to the date of death due to any cause. OS analysis will be performed by CD8 subgroups with the median and quartiles of baseline CD8 expression as cut-offs.

Lung Cancer Specific Survival (LCSS)

LCSS is defined as the time from date of randomization to the date of death due to lung cancer.

Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of canakinumab

To characterize the pharmacokinetics of canakinumab therapy. AUClast will be calculated from serum concentration-time data.

Maximum Observed Plasma Concentration (Cmax) of canakinumab

To characterize the pharmacokinetics of canakinumab therapy. Cmax will be calculated from serum concentration-time data.

Trough Concentration (Cmin) of canakinumab

To characterize the pharmacokinetics of canakinumab therapy. Cmin will be calculated from serum concentration-time data.

Anti-drug Antibody (ADA) prevalence at baseline

Immunogenicity to canakinumab prior to canakinumab exposure. ADA prevalence at baseline wil be calculated as the proportion of participants who had an ADA positive result at baseline

Anti-drug Antibody (ADA) incidence

ADA incidence on treatment will be calculated as the proportion of participants who were treatment-induced ADA positive (post-baseline ADA positive with ADA-negative sample at baseline) and treatment-boosted ADA positive (post-baseline ADA positive with titer that is at least the fold titer change greater than the ADA-positive baseline titer)

Time to definitive 10 point deterioration symptom scores of pain,cough and dyspnea per EORTC QLQ-LC13 questionnaire

The Lung Cancer module of the EORTC's quality of life questionnaire (EORTC QLQ-LC13) is used in conjunction with the EORTC QLQ-C30 and provides information on an additional 13 items specifically related to lung cancer. The lung cancer module incorporates one multi-item scale to assess dyspnea, and 9 single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. All of the domain scores range from 0 to 100. A high score indicates a high level of symptoms. The time to definitive 10 point deterioration symptom scores of pain, cough and dyspnea is defined as the time from the date of randomization to the date of event, which is defined as at least 10 points relative to baseline worsening of the EORTC QLQ-LC13 symptom score with no later change below this thereshold or death due to any cause, whichever occurs earlier

Time to definitive 10 point deterioration of global health status/QoL, shortness of breath and pain per EORTC QLQ-C30 questionnaire

The EORTC QLQ-C30 is a questionnaire developed to assess the health-related quality of life of cancer participants. It assesses 15 domains consisting of 5 functional domains (physical, role, emotional, cognitive, social) and 9 symptom domains (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties) and a global health status/quality of life (QoL) scale. All of the domain scores range from 0 to 100. A high score for a functional scale indicates a high and healthy level of functioning but a high score for a symptom scale indicates a high level of symptoms. The time to definitive 10 point deterioration of global health status/QoL, shortness of breath and pain is defined as the time from the date of randomization to the date of event, which is defined as at least 10 points relative to baseline worsening of the EORTC QLQ-C30 score with no later change below this threshold or death due to any cause, whichever occurs earlier.

Time to first 10 point deterioration for symptom scores of pain, cough and dyspnea per EORTC QLQ-LC13 questionnaire

The Lung Cancer module of the EORTC's quality of life questionnaire (EORTC QLQ-LC13) is used in conjunction with the EORTC QLQ-C30 and provides information on an additional 13 items specifically related to lung cancer. The lung cancer module incorporates one multi-item scale to assess dyspnea, and 9 single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. All of the domain scores range from 0 to 100. A high score indicates a high level of symptoms. The time to first 10 point deterioration symptom scores of pain, cough and dyspnea is defined as the time from the date of randomization to the first onset of at least 10 points absolute increase from baseline (worsening) in symptoms scores or death due to any cause, whichever occurs earlier.

Time to first 10 point deterioration of global health status/QoL, shortness of breath and pain per EORTC QLQ-C30 questionnaire

The EORTC QLQ-C30 is a questionnaire developed to assess the health-related quality of life of cancer participants. It assesses 15 domains consisting of 5 functional domains (physical, role, emotional, cognitive, social) and 9 symptom domains (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties) and a global health status/quality of life (QoL) scale. All of the domain scores range from 0 to 100. A high score for a functional scale indicates a high and healthy level of functioning but a high score for a symptom scale indicates a high level of symptoms. The time to first 10 point deterioration of global health status/QoL, shortness of breath and pain scores is defined as the time from the date of randomization to the first onset of at least 10 points absolute increase from baseline (worsening) in symptoms scores or death due to any cause, whichever occurs earlier.

Utility scores of the EQ-5D-5L

EQ-5D-5L is a standardized participant completed questionnaire that measures health-related quality of life and translates that score into an index value or utility score. EQ-5D-5L consists of two components: a health state profile and an optional visual analogue scale (VAS). EQ-5D health state profile is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, and 5= extreme problems. Higher scores indicated greater levels of problems across each of the five dimensions.

Full Information

NCT ID

NCT03447769

First Posted

February 19, 2018

Last Updated

February 28, 2023

Sponsor

Novartis Pharmaceuticals

1. Study Identification

Unique Protocol Identification Number

NCT03447769

Brief Title

Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A

Acronym

Canopy-A

Official Title

A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)

Study Type

Interventional

2. Study Status

Record Verification Date

February 2023

Overall Recruitment Status

Terminated

Why Stopped

Upon review of the primary analysis results, the benefit-risk was assessed by the Steering Committee Members with the decision that the study will be closed. No new safety signals were observed for canakinumab

Study Start Date

March 16, 2018 (Actual)

Primary Completion Date

March 17, 2022 (Actual)

Study Completion Date

February 7, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Novartis Pharmaceuticals

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Yes

Studies a U.S. FDA-regulated Device Product

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

The primary purpose of the study is to compare the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II -IIIA and the subset of IIIB (T>5cm N2 disease) completely resected (R0) non-small cell lung cancer (NSCLC).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Non-Small Cell Lung Cancer

Keywords

Non-Small Cell Lung Cancer, NSCLC, ACZ885, canakinumab, adjuvant, AJCC/UICC v. 8 stages II-IIIA and IIIB (T>5cm N2)

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 3

Interventional Study Model

Parallel Assignment

Masking

ParticipantCare ProviderInvestigatorOutcomes Assessor

Allocation

Randomized

Enrollment

1382 (Actual)

8. Arms, Groups, and Interventions

Arm Title

canakinumab

Arm Type

Experimental

Arm Description

Participants will receive canakinumab for 18 cycles (approximately 54 weeks).

Arm Title

Placebo

Arm Type

Placebo Comparator

Arm Description

Participants will receive canakinumab placebo for 18 cycles (approximately 54 weeks).

Intervention Type

Drug

Intervention Name(s)

Canakinumab

Other Intervention Name(s)

ACZ885

Intervention Description

Canakinumab will be administered periodically for approximately 54 weeks.

Intervention Type

Drug

Intervention Name(s)

Placebo

Intervention Description

Placebo will be administered periodically for approximately 54 weeks.

Primary Outcome Measure Information:

Title

Disease free survival (DFS) by local investigator

Description

DFS is the time from the date of randomization to the date of the first documented NSCLC disease recurrence as assessed by local investigator radiologically or death due to any cause.

Time Frame

Up to approximately 5 years

Secondary Outcome Measure Information:

Title

Overall Survival (OS)

Description

Overall Survival (OS) is the time from the date of randomization to the date of death due to any cause.

Time Frame

Up to approximately 5 years

Title

Disease free survival (DFS) by local investigator in PD-L1 subgroups

Description

Time Frame

Up to approximately 5 years

Title

Disease free survival (DFS) by local investigator in CD8 subgroups

Description

DFS is the time from the date of randomization to the date of the first documented NSCLC disease recurrence as assessed by local investigator radiologically or death due to any cause. DFS analysis will be performed by CD8 subgroups with the median and quartiles of baseline CD8 expression as cut-offs.

Time Frame

Up to approximately 5 years

Title

Overall Survival (OS) by local investigator in PD-L1 subgroups

Description

Time Frame

up to approximately 5 years

Title

Overall Survival (OS) by local investigator in CD8 subgroups

Description

Time Frame

up to approximately 5 years

Title

Lung Cancer Specific Survival (LCSS)

Description

LCSS is defined as the time from date of randomization to the date of death due to lung cancer.

Time Frame

up to approximately 5 years

Title

Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of canakinumab

Description

To characterize the pharmacokinetics of canakinumab therapy. AUClast will be calculated from serum concentration-time data.

Time Frame

Up to approximately 5 years

Title

Maximum Observed Plasma Concentration (Cmax) of canakinumab

Description

To characterize the pharmacokinetics of canakinumab therapy. Cmax will be calculated from serum concentration-time data.

Time Frame

Up to approximately 5 years

Title

Trough Concentration (Cmin) of canakinumab

Description

To characterize the pharmacokinetics of canakinumab therapy. Cmin will be calculated from serum concentration-time data.

Time Frame

Up to approximately 5 years

Title

Anti-drug Antibody (ADA) prevalence at baseline

Description

Immunogenicity to canakinumab prior to canakinumab exposure. ADA prevalence at baseline wil be calculated as the proportion of participants who had an ADA positive result at baseline

Time Frame

Baseline

Title

Anti-drug Antibody (ADA) incidence

Description

Time Frame

Up to approximately 5 years

Title

Time to definitive 10 point deterioration symptom scores of pain,cough and dyspnea per EORTC QLQ-LC13 questionnaire

Description

Time Frame

Up to approximately 5 years

Title

Time to definitive 10 point deterioration of global health status/QoL, shortness of breath and pain per EORTC QLQ-C30 questionnaire

Description

Time Frame

Up to approximately 5 years

Title

Time to first 10 point deterioration for symptom scores of pain, cough and dyspnea per EORTC QLQ-LC13 questionnaire

Description

The Lung Cancer module of the EORTC's quality of life questionnaire (EORTC QLQ-LC13) is used in conjunction with the EORTC QLQ-C30 and provides information on an additional 13 items specifically related to lung cancer. The lung cancer module incorporates one multi-item scale to assess dyspnea, and 9 single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. All of the domain scores range from 0 to 100. A high score indicates a high level of symptoms. The time to first 10 point deterioration symptom scores of pain, cough and dyspnea is defined as the time from the date of randomization to the first onset of at least 10 points absolute increase from baseline (worsening) in symptoms scores or death due to any cause, whichever occurs earlier.

Time Frame

Up to approximately 5 years

Title

Time to first 10 point deterioration of global health status/QoL, shortness of breath and pain per EORTC QLQ-C30 questionnaire

Description

The EORTC QLQ-C30 is a questionnaire developed to assess the health-related quality of life of cancer participants. It assesses 15 domains consisting of 5 functional domains (physical, role, emotional, cognitive, social) and 9 symptom domains (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties) and a global health status/quality of life (QoL) scale. All of the domain scores range from 0 to 100. A high score for a functional scale indicates a high and healthy level of functioning but a high score for a symptom scale indicates a high level of symptoms. The time to first 10 point deterioration of global health status/QoL, shortness of breath and pain scores is defined as the time from the date of randomization to the first onset of at least 10 points absolute increase from baseline (worsening) in symptoms scores or death due to any cause, whichever occurs earlier.

Time Frame

Up to approximately 5 years

Title

Utility scores of the EQ-5D-5L

Description

Time Frame

Up to approximately 5 years

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Have completely resected (R0) NSCLC AJCC/UICC v. 8 stage IIA-IIIA and IIIB (N2 disease only) OR have NSCLC Stage IIA-IIIA, IIIB (N2 disease only) and are candidates for complete resection surgery Cisplatin-based chemotherapy is mandatory for all subjects (Exception: In subjects with stage IIA disease with no nodal involvement, cisplatin-based chemotherapy can be administered if recommended by the treating physician). When required, a minimum of two cycles of cisplatin-based chemotherapy is mandatory, after which additional therapies can be given based upon local clinical practice and/or guidelines. Typically, chemotherapy is initiated within 60 days of surgery. Must have recovered from all toxicities related to prior systemic therapy to grade ≤ 1 (CTCAE v 4.03). Exception to this criterion: subjects with any grade of alopecia and grade 2 or less neuropathy are allowed to enter the study Have ECOG performance status (PS) of 0 or 1 Exclusion Criteria: Have unresectable or metastatic disease, positive microscopic margins on the pathology report, and/or gross disease remaining at the time of surgery Have received any neoadjuvant therapy Presence or history of a malignant disease, other than the resected NSCLC, that has been diagnosed and/or required therapy within the past 3 years Exceptions to this exclusion include the following: completely resected basal cell and squamous cell skin cancers, completely resected carcinoma in situ of any type and hormonal maintenance for breast and prostate cancer > 3 years. Have a history of current diagnosis of cardiac disease Have uncontrolled diabetes Have known active or recurrent hepatic disorder including cirrhosis, hepatitis B and C (positive or indeterminate central laboratory results) Subjects must be evaluated for tuberculosis as per local treatment guidelines or clinical practice. Subjects with active tuberculosis are not eligible. Have suspected or proven immunocompromised state as described in the protocol Had Live and attenuated vaccination within 3 months prior to first dose of study drug (e.g. MMR, Yellow Fever, Rotavirus, Smallpox, etc.). Other inclusion/exclusion criteria may apply

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Novartis Pharmaceuticals

Organizational Affiliation

Novartis Pharmaceuticals

Official's Role

Study Director

Facility Information:

Facility Name

Highlands Oncology Group

City

Fayetteville

State/Province

Arkansas

ZIP/Postal Code

72703

Country

United States

Facility Name

Cancer and Blood Specialty Clinic

City

Los Alamitos

State/Province

California

ZIP/Postal Code

90720

Country

United States

Facility Name

University of California at Los Angeles

City

Los Angeles

State/Province

California

ZIP/Postal Code

90095

Country

United States

Facility Name

VA Palo Alto Health Care System CRLX030A2301

City

Palo Alto

State/Province

California

ZIP/Postal Code

94304-1207

Country

United States

Facility Name

Sansum Clinic

City

Santa Barbara

State/Province

California

ZIP/Postal Code

93105

Country

United States

Facility Name

Rocky Mountain Cancer Centers Denver-Mdtn(Bone&MarrowTransp)

City

Longmont

State/Province

Colorado

ZIP/Postal Code

80501

Country

United States

Facility Name

Florida Cancer Specialists

City

Fort Myers

State/Province

Florida

ZIP/Postal Code

33901

Country

United States

Facility Name

Advanced Medical Specialties Drug Ship - 2

City

Miami

State/Province

Florida

ZIP/Postal Code

33176

Country

United States

Facility Name

Florida Cancer Affiliates of Ocala

City

Ocala

State/Province

Florida

ZIP/Postal Code

34471

Country

United States

Facility Name

Florida Cancer Specialists North

City

Saint Petersburg

State/Province

Florida

ZIP/Postal Code

33705

Country

United States

Facility Name

Florida Cancer Specialists Panhandle

City

Tallahassee

State/Province

Florida

ZIP/Postal Code

32308

Country

United States

Facility Name

Florida Cancer Specialists

City

West Palm Beach

State/Province

Florida

ZIP/Postal Code

33401

Country

United States

Facility Name

Rush University Medical Center CLDT600AUS06

City

Chicago

State/Province

Illinois

ZIP/Postal Code

60612

Country

United States

Facility Name

Cancer Center of Kansas Dept.ofCancerCtr.ofKansas

City

Wichita

State/Province

Kansas

ZIP/Postal Code

67214-3728

Country

United States

Facility Name

VA Nebraska-Western Iowa Health Care System

City

Omaha

State/Province

Nebraska

ZIP/Postal Code

68105

Country

United States

Facility Name

Louis Stokes Cleveland Department of Veterans Affairs MC

City

Cleveland

State/Province

Ohio

ZIP/Postal Code

44106

Country

United States

Facility Name

Oncology Associates of Oregon, PC

City

Eugene

State/Province

Oregon

ZIP/Postal Code

97401-8122

Country

United States

Facility Name

Chattanooga Oncology and Hematology Associates PC Chattanooga Oncology

City

Chattanooga

State/Province

Tennessee

ZIP/Postal Code

37404

Country

United States

Facility Name

Sarah Cannon Research Institute

City

Nashville

State/Province

Tennessee

ZIP/Postal Code

37203

Country

United States

Facility Name

VA North Texas Health Care System

City

Dallas

State/Province

Texas

ZIP/Postal Code

75216

Country

United States

Facility Name

Texas Oncology MamieMcFaddenWardCtr

City

Dallas

State/Province

Texas

ZIP/Postal Code

75246

Country

United States

Facility Name

Virginia Cancer Specialists Fairfax Northern Virginia

City

Fairfax

State/Province

Virginia

ZIP/Postal Code

22031

Country

United States

Facility Name

Oncology and Hematology Associates of Southwest Virginia Inc

City

Salem

State/Province

Virginia

ZIP/Postal Code

24153

Country

United States

Facility Name

Novartis Investigative Site

City

Caba

State/Province

Buenos Aires

ZIP/Postal Code

C1426ANZ

Country

Argentina

Facility Name

Novartis Investigative Site

City

Mar del Plata

State/Province

Buenos Aires

ZIP/Postal Code

B7600FZN

Country

Argentina

Facility Name

Novartis Investigative Site

City

Rosario

State/Province

Santa Fe

ZIP/Postal Code

S2000DSV

Country

Argentina

Facility Name

Novartis Investigative Site

City

Rosario

State/Province

Sante Fe

ZIP/Postal Code

S200KZE

Country

Argentina

Facility Name

Novartis Investigative Site

City

Cordoba

ZIP/Postal Code

X5016KEH

Country

Argentina

Facility Name

Novartis Investigative Site

City

Graz

ZIP/Postal Code

8036

Country

Austria

Facility Name

Novartis Investigative Site

City

Klagenfurt

ZIP/Postal Code

9020

Country

Austria

Facility Name

Novartis Investigative Site

City

Krems

ZIP/Postal Code

A-3500

Country

Austria

Facility Name

Novartis Investigative Site

City

Vienna

ZIP/Postal Code

A-1090

Country

Austria

Facility Name

Novartis Investigative Site

City

Teresina

State/Province

Piaui

ZIP/Postal Code

64049-200

Country

Brazil

Facility Name

Novartis Investigative Site

City

Londrina

State/Province

ZIP/Postal Code

86015-520

Country

Brazil

Facility Name

Novartis Investigative Site

City

Barretos

State/Province

ZIP/Postal Code

14784 400

Country

Brazil

Facility Name

Novartis Investigative Site

City

Sao Paulo

State/Province

ZIP/Postal Code

01246 000

Country

Brazil

Facility Name

Novartis Investigative Site

City

Sao Paulo

State/Province

ZIP/Postal Code

04014-002

Country

Brazil

Facility Name

Novartis Investigative Site

City

Sofia

ZIP/Postal Code

1303

Country

Bulgaria

Facility Name

Novartis Investigative Site

City

Sofia

ZIP/Postal Code

1407

Country

Bulgaria

Facility Name

Novartis Investigative Site

City

Sofia

ZIP/Postal Code

1756

Country

Bulgaria

Facility Name

Novartis Investigative Site

City

Sofia

ZIP/Postal Code

1784

Country

Bulgaria

Facility Name

Novartis Investigative Site

City

Edmonton

State/Province

Alberta

ZIP/Postal Code

T6G 1Z2

Country

Canada

Facility Name

Novartis Investigative Site

City

Moncton

State/Province

New Brunswick

ZIP/Postal Code

E1C 6Z8

Country

Canada

Facility Name

Novartis Investigative Site

City

Halifax

State/Province

Nova Scotia

ZIP/Postal Code

B3H 1V7

Country

Canada

Facility Name

Novartis Investigative Site

City

Montreal

State/Province

Quebec

ZIP/Postal Code

H2W 1T8

Country

Canada

Facility Name

Novartis Investigative Site

City

Quebec

ZIP/Postal Code

GIV 4G5

Country

Canada

Facility Name

Novartis Investigative Site

City

Santiago

ZIP/Postal Code

7500921

Country

Chile

Facility Name

Novartis Investigative Site

City

Santiago

Country

Chile

Facility Name

Novartis Investigative Site

City

Hefei

State/Province

Anhui

ZIP/Postal Code

230001

Country

China

Facility Name

Novartis Investigative Site

City

Beijing

State/Province

Beijing

ZIP/Postal Code

100039

Country

China

Facility Name

Novartis Investigative Site

City

Chongqing

State/Province

Chongqing

ZIP/Postal Code

400037

Country

China

Facility Name

Novartis Investigative Site

City

Guangzhou

State/Province

Guangdong

ZIP/Postal Code

510000

Country

China

Facility Name

Novartis Investigative Site

City

Shenzhen

State/Province

Guangdong

ZIP/Postal Code

518020

Country

China

Facility Name

Novartis Investigative Site

City

Zhanjing

State/Province

Guangong

ZIP/Postal Code

524000

Country

China

Facility Name

Novartis Investigative Site

City

Zunyi

State/Province

Guizhou

Country

China

Facility Name

Novartis Investigative Site

City

Zhengzhou

State/Province

Henan

ZIP/Postal Code

450008

Country

China

Facility Name

Novartis Investigative Site

City

Nanjing

State/Province

Jiangsu

ZIP/Postal Code

210008

Country

China

Facility Name

Novartis Investigative Site

City

Suzhou

State/Province

Jiangsu

ZIP/Postal Code

215004

Country

China

Facility Name

Novartis Investigative Site

City

Chang Chun

State/Province

Jilin

ZIP/Postal Code

130021

Country

China

Facility Name

Novartis Investigative Site

City

Shenyang

State/Province

Liaoning

ZIP/Postal Code

110011

Country

China

Facility Name

Novartis Investigative Site

City

Jinan

State/Province

Shandong

ZIP/Postal Code

250117

Country

China

Facility Name

Novartis Investigative Site

City

Shanghai

State/Province

Shanghai

ZIP/Postal Code

200032

Country

China

Facility Name

Novartis Investigative Site

City

Shanghai

State/Province

Shanghai

ZIP/Postal Code

200433

Country

China

Facility Name

Novartis Investigative Site

City

XI An

State/Province

Shanxi

ZIP/Postal Code

710061

Country

China

Facility Name

Novartis Investigative Site

City

Shenyang

State/Province

Shengyang

ZIP/Postal Code

110041

Country

China

Facility Name

Novartis Investigative Site

City

Chengdu

State/Province

Sichuan

ZIP/Postal Code

610041

Country

China

Facility Name

Novartis Investigative Site

City

Hangzhou

State/Province

Zhejiang

ZIP/Postal Code

310003

Country

China

Facility Name

Novartis Investigative Site

City

Hangzhou

State/Province

Zhejiang

ZIP/Postal Code

310022

Country

China

Facility Name

Novartis Investigative Site

City

Beijing

ZIP/Postal Code

100036

Country

China

Facility Name

Novartis Investigative Site

City

Changsha

ZIP/Postal Code

410013

Country

China

Facility Name

Novartis Investigative Site

City

Chengdu

Country

China

Facility Name

Novartis Investigative Site

City

Fujian

ZIP/Postal Code

350001

Country

China

Facility Name

Novartis Investigative Site

City

Tianjin

ZIP/Postal Code

300000

Country

China

Facility Name

Novartis Investigative Site

City

Tianjin

ZIP/Postal Code

300052

Country

China

Facility Name

Novartis Investigative Site

City

Bogota

ZIP/Postal Code

110221

Country

Colombia

Facility Name

Novartis Investigative Site

City

Ostrava Vitkovice

ZIP/Postal Code

703 84

Country

Czechia

Facility Name

Novartis Investigative Site

City

Prague 2

ZIP/Postal Code

128 21

Country

Czechia

Facility Name

Novartis Investigative Site

City

Marseille cedex 20

State/Province

Bouches Du Rhone

ZIP/Postal Code

13915

Country

France

Facility Name

Novartis Investigative Site

City

Le Mans

State/Province

Cedex 09

ZIP/Postal Code

72037

Country

France

Facility Name

Novartis Investigative Site

City

Montpellier cedex 5

State/Province

Herault

ZIP/Postal Code

34059

Country

France

Facility Name

Novartis Investigative Site

City

Amiens

ZIP/Postal Code

80054

Country

France

Facility Name

Novartis Investigative Site

City

Angers Cedex 9

ZIP/Postal Code

49933

Country

France

Facility Name

Novartis Investigative Site

City

Avignon Cedex

ZIP/Postal Code

84902

Country

France

Facility Name

Novartis Investigative Site

City

Bayonne

ZIP/Postal Code

64109

Country

France

Facility Name

Novartis Investigative Site

City

Brest

ZIP/Postal Code

29200

Country

France

Facility Name

Novartis Investigative Site

City

Bron

ZIP/Postal Code

69677

Country

France

Facility Name

Novartis Investigative Site

City

Clermont-Ferrand

ZIP/Postal Code

63000

Country

France

Facility Name

Novartis Investigative Site

City

Creteil

ZIP/Postal Code

94000

Country

France

Facility Name

Novartis Investigative Site

City

La Rochelle

ZIP/Postal Code

17019

Country

France

Facility Name

Novartis Investigative Site

City

La Seyne sur mer

ZIP/Postal Code

83500

Country

France

Facility Name

Novartis Investigative Site

City

Lille

ZIP/Postal Code

59000

Country

France

Facility Name

Novartis Investigative Site

City

Paris

ZIP/Postal Code

75231

Country

France

Facility Name

Novartis Investigative Site

City

Paris

ZIP/Postal Code

75679

Country

France

Facility Name

Novartis Investigative Site

City

Pessac

ZIP/Postal Code

33604

Country

France

Facility Name

Novartis Investigative Site

City

Poitiers

ZIP/Postal Code

86000

Country

France

Facility Name

Novartis Investigative Site

City

Saint-Herblain Cédex

ZIP/Postal Code

44805

Country

France

Facility Name

Novartis Investigative Site

City

Strasbourg Cedex

ZIP/Postal Code

67091

Country

France

Facility Name

Novartis Investigative Site

City

Suresnes

ZIP/Postal Code

92150

Country

France

Facility Name

Novartis Investigative Site

City

Toulouse

ZIP/Postal Code

31400

Country

France

Facility Name

Novartis Investigative Site

City

Batumi

ZIP/Postal Code

6000

Country

Georgia

Facility Name

Novartis Investigative Site

City

Tbilisi

ZIP/Postal Code

0144

Country

Georgia

Facility Name

Novartis Investigative Site

City

Tbilisi

ZIP/Postal Code

0159

Country

Georgia

Facility Name

Novartis Investigative Site

City

Tbilisi

ZIP/Postal Code

0160

Country

Georgia

Facility Name

Novartis Investigative Site

City

Tbilisi

ZIP/Postal Code

112

Country

Georgia

Facility Name

Novartis Investigative Site

City

Heidelberg

State/Province

Baden-Württemberg

ZIP/Postal Code

69126

Country

Germany

Facility Name

Novartis Investigative Site

City

Gauting

State/Province

Bayern

ZIP/Postal Code

82131

Country

Germany

Facility Name

Novartis Investigative Site

City

Bochum

State/Province

Nordrhein Westfalen

ZIP/Postal Code

44791

Country

Germany

Facility Name

Novartis Investigative Site

City

Velbert

State/Province

North Rhine-westphalia

ZIP/Postal Code

42551

Country

Germany

Facility Name

Novartis Investigative Site

City

Aachen

ZIP/Postal Code

52074

Country

Germany

Facility Name

Novartis Investigative Site

City

Berlin

ZIP/Postal Code

12351

Country

Germany

Facility Name

Novartis Investigative Site

City

Berlin

ZIP/Postal Code

13125

Country

Germany

Facility Name

Novartis Investigative Site

City

Berlin

ZIP/Postal Code

14165

Country

Germany

Facility Name

Novartis Investigative Site

City

Chemnitz

ZIP/Postal Code

09113

Country

Germany

Facility Name

Novartis Investigative Site

City

Dresden

ZIP/Postal Code

01307

Country

Germany

Facility Name

Novartis Investigative Site

City

Erfurt

ZIP/Postal Code

99089

Country

Germany

Facility Name

Novartis Investigative Site

City

Essen

ZIP/Postal Code

45147

Country

Germany

Facility Name

Novartis Investigative Site

City

Georgsmarienhuette

ZIP/Postal Code

49124

Country

Germany

Facility Name

Novartis Investigative Site

City

Gera

ZIP/Postal Code

07548

Country

Germany

Facility Name

Novartis Investigative Site

City

Gerlingen

ZIP/Postal Code

70839

Country

Germany

Facility Name

Novartis Investigative Site

City

Grosshansdorf

ZIP/Postal Code

22947

Country

Germany

Facility Name

Novartis Investigative Site

City

Halle (Saale)

ZIP/Postal Code

06120

Country

Germany

Facility Name

Novartis Investigative Site

City

Koeln

ZIP/Postal Code

51109

Country

Germany

Facility Name

Novartis Investigative Site

City

Leipzig

ZIP/Postal Code

D-04347

Country

Germany

Facility Name

Novartis Investigative Site

City

Minden

ZIP/Postal Code

32429

Country

Germany

Facility Name

Novartis Investigative Site

City

Muenchen

ZIP/Postal Code

81377

Country

Germany

Facility Name

Novartis Investigative Site

City

Nuernberg

ZIP/Postal Code

90419

Country

Germany

Facility Name

Novartis Investigative Site

City

Solingen

ZIP/Postal Code

42699

Country

Germany

Facility Name

Novartis Investigative Site

City

Ulm

ZIP/Postal Code

89081

Country

Germany

Facility Name

Novartis Investigative Site

City

Wuerzburg

ZIP/Postal Code

97074

Country

Germany

Facility Name

Novartis Investigative Site

City

Athens

State/Province

Attica

ZIP/Postal Code

15562

Country

Greece

Facility Name

Novartis Investigative Site

City

Athens

State/Province

ZIP/Postal Code

115 27

Country

Greece

Facility Name

Novartis Investigative Site

City

Athens

ZIP/Postal Code

11526

Country

Greece

Facility Name

Novartis Investigative Site

City

Athens

ZIP/Postal Code

18547

Country

Greece

Facility Name

Novartis Investigative Site

City

Athens

ZIP/Postal Code

GR14564

Country

Greece

Facility Name

Novartis Investigative Site

City

Thessaloniki

ZIP/Postal Code

57001

Country

Greece

Facility Name

Novartis Investigative Site

City

Hong Kong

Country

Hong Kong

Facility Name

Novartis Investigative Site

City

Kowloon

Country

Hong Kong

Facility Name

Novartis Investigative Site

City

Tuen Mun

Country

Hong Kong

Facility Name

Novartis Investigative Site

City

Torokbalint

State/Province

Pest

ZIP/Postal Code

2045

Country

Hungary

Facility Name

Novartis Investigative Site

City

Veszprem

ZIP/Postal Code

8200

Country

Hungary

Facility Name

Novartis Investigative Site

City

Reykjavik

ZIP/Postal Code

IS-101

Country

Iceland

Facility Name

Novartis Investigative Site

City

Mumbai

State/Province

Maharashtra

ZIP/Postal Code

400022

Country

India

Facility Name

Novartis Investigative Site

City

Nashik

State/Province

Maharashtra

ZIP/Postal Code

422 004

Country

India

Facility Name

Novartis Investigative Site

City

Kolkata

State/Province

West Bengal

ZIP/Postal Code

700160

Country

India

Facility Name

Novartis Investigative Site

City

Delhi

ZIP/Postal Code

110 085

Country

India

Facility Name

Novartis Investigative Site

City

Haifa

ZIP/Postal Code

3109601

Country

Israel

Facility Name

Novartis Investigative Site

City

Holon

ZIP/Postal Code

58100

Country

Israel

Facility Name

Novartis Investigative Site

City

Ancona

State/Province

ZIP/Postal Code

60126

Country

Italy

Facility Name

Novartis Investigative Site

City

Bari

State/Province

ZIP/Postal Code

70124

Country

Italy

Facility Name

Novartis Investigative Site

City

Meldola

State/Province

ZIP/Postal Code

47014

Country

Italy

Facility Name

Novartis Investigative Site

City

Monza

State/Province

ZIP/Postal Code

20900

Country

Italy

Facility Name

Novartis Investigative Site

City

Milano

State/Province

ZIP/Postal Code

20132

Country

Italy

Facility Name

Novartis Investigative Site

City

Milano

State/Province

ZIP/Postal Code

20133

Country

Italy

Facility Name

Novartis Investigative Site

City

Padova

State/Province

ZIP/Postal Code

35100

Country

Italy

Facility Name

Novartis Investigative Site

City

Perugia

State/Province

ZIP/Postal Code

06129

Country

Italy

Facility Name

Novartis Investigative Site

City

Aviano

State/Province

ZIP/Postal Code

33081

Country

Italy

Facility Name

Novartis Investigative Site

City

Ravenna

State/Province

ZIP/Postal Code

48100

Country

Italy

Facility Name

Novartis Investigative Site

City

Roma

State/Province

ZIP/Postal Code

00189

Country

Italy

Facility Name

Novartis Investigative Site

City

Orbassano

State/Province

ZIP/Postal Code

10043

Country

Italy

Facility Name

Novartis Investigative Site

City

Nagoya

State/Province

Aichi

ZIP/Postal Code

464 8681

Country

Japan

Facility Name

Novartis Investigative Site

City

Nagoya

State/Province

Aichi

ZIP/Postal Code

466 8560

Country

Japan

Facility Name

Novartis Investigative Site

City

Hirosaki

State/Province

Aomori

ZIP/Postal Code

036 8563

Country

Japan

Facility Name

Novartis Investigative Site

City

Matsuyama

State/Province

Ehime

ZIP/Postal Code

791-0280

Country

Japan

Facility Name

Novartis Investigative Site

City

Iizuka-city

State/Province

Fukuoka

ZIP/Postal Code

820-8505

Country

Japan

Facility Name

Novartis Investigative Site

City

Asahikawa-city

State/Province

Hokkaido

ZIP/Postal Code

070-8644

Country

Japan

Facility Name

Novartis Investigative Site

City

Sapporo city

State/Province

Hokkaido

ZIP/Postal Code

060 8648

Country

Japan

Facility Name

Novartis Investigative Site

City

Himeji

State/Province

Hyogo

ZIP/Postal Code

670-8520

Country

Japan

Facility Name

Novartis Investigative Site

City

Kanazawa-city

State/Province

Ishikawa

ZIP/Postal Code

920-8641

Country

Japan

Facility Name

Novartis Investigative Site

City

Shiwa-gun

State/Province

Iwate

ZIP/Postal Code

028-3695

Country

Japan

Facility Name

Novartis Investigative Site

City

Yokohama-city

State/Province

Kanagawa

ZIP/Postal Code

236 0051

Country

Japan

Facility Name

Novartis Investigative Site

City

Yokohama-city

State/Province

Kanagawa

ZIP/Postal Code

241-8515

Country

Japan

Facility Name

Novartis Investigative Site

City

Natori

State/Province

Miyagi

ZIP/Postal Code

981-1293

Country

Japan

Facility Name

Novartis Investigative Site

City

Hirakata-city

State/Province

Osaka

ZIP/Postal Code

573-1191

Country

Japan

Facility Name

Novartis Investigative Site

City

Osaka-city

State/Province

Osaka

ZIP/Postal Code

541-8567

Country

Japan

Facility Name

Novartis Investigative Site

City

Sakai

State/Province

Osaka

ZIP/Postal Code

591-8555

Country

Japan

Facility Name

Novartis Investigative Site

City

Hidaka-city

State/Province

Saitama

ZIP/Postal Code

350-1298

Country

Japan

Facility Name

Novartis Investigative Site

City

Sunto Gun

State/Province

Shizuoka

ZIP/Postal Code

411 8777

Country

Japan

Facility Name

Novartis Investigative Site

City

Bunkyo ku

State/Province

Tokyo

ZIP/Postal Code

113-8431

Country

Japan

Facility Name

Novartis Investigative Site

City

Chuo ku

State/Province

Tokyo

ZIP/Postal Code

104 0045

Country

Japan

Facility Name

Novartis Investigative Site

City

Minato ku

State/Province

Tokyo

ZIP/Postal Code

105-8470

Country

Japan

Facility Name

Novartis Investigative Site

City

Wakayama-city

State/Province

Wakayama

ZIP/Postal Code

641-8510

Country

Japan

Facility Name

Novartis Investigative Site

City

Ube-city

State/Province

Yamaguchi

ZIP/Postal Code

755-0241

Country

Japan

Facility Name

Novartis Investigative Site

City

Fukuoka

ZIP/Postal Code

810-8563

Country

Japan

Facility Name

Novartis Investigative Site

City

Osaka

ZIP/Postal Code

545-8586

Country

Japan

Facility Name

Novartis Investigative Site

City

Amman

ZIP/Postal Code

11941

Country

Jordan

Facility Name

Novartis Investigative Site

City

Cheongju si

State/Province

Chungcheongbuk Do

ZIP/Postal Code

28644

Country

Korea, Republic of

Facility Name

Novartis Investigative Site

City

Jeollanam-do

State/Province

Korea

ZIP/Postal Code

58128

Country

Korea, Republic of

Facility Name

Novartis Investigative Site

City

Seoul

State/Province

Korea

ZIP/Postal Code

08308

Country

Korea, Republic of

Facility Name

Novartis Investigative Site

City

Busan

ZIP/Postal Code

48108

Country

Korea, Republic of

Facility Name

Novartis Investigative Site

City

Seoul

ZIP/Postal Code

03080

Country

Korea, Republic of

Facility Name

Novartis Investigative Site

City

Seoul

ZIP/Postal Code

03722

Country

Korea, Republic of

Facility Name

Novartis Investigative Site

City

Seoul

ZIP/Postal Code

05505

Country

Korea, Republic of

Facility Name

Novartis Investigative Site

City

Ashrafieh

ZIP/Postal Code

166830

Country

Lebanon

Facility Name

Novartis Investigative Site

City

Beirut

Country

Lebanon

Facility Name

Novartis Investigative Site

City

Saida

ZIP/Postal Code

652

Country

Lebanon

Facility Name

Novartis Investigative Site

City

Tripoli

ZIP/Postal Code

1434

Country

Lebanon

Facility Name

Novartis Investigative Site

City

Kuching

State/Province

Sarawak

ZIP/Postal Code

93586

Country

Malaysia

Facility Name

Novartis Investigative Site

City

Kuala Lumpur

ZIP/Postal Code

59100

Country

Malaysia

Facility Name

Novartis Investigative Site

City

Pulau Pinang

ZIP/Postal Code

10990

Country

Malaysia

Facility Name

Novartis Investigative Site

City

Bergen

ZIP/Postal Code

5021

Country

Norway

Facility Name

Novartis Investigative Site

City

Drammen

ZIP/Postal Code

3004

Country

Norway

Facility Name

Novartis Investigative Site

City

Oslo

ZIP/Postal Code

0424

Country

Norway

Facility Name

Novartis Investigative Site

City

Tromso

ZIP/Postal Code

9019

Country

Norway

Facility Name

Novartis Investigative Site

City

Panama City

ZIP/Postal Code

0801

Country

Panama

Facility Name

Novartis Investigative Site

City

San Borja

State/Province

Lima

ZIP/Postal Code

Country

Peru

Facility Name

Novartis Investigative Site

City

Surquillo

State/Province

Lima

ZIP/Postal Code

Country

Peru

Facility Name

Novartis Investigative Site

City

Makati City

ZIP/Postal Code

1229

Country

Philippines

Facility Name

Novartis Investigative Site

City

Krakow

State/Province

Ma3opolska

ZIP/Postal Code

31-826

Country

Poland

Facility Name

Novartis Investigative Site

City

Konin

ZIP/Postal Code

62 500

Country

Poland

Facility Name

Novartis Investigative Site

City

Olsztyn

ZIP/Postal Code

10-288

Country

Poland

Facility Name

Novartis Investigative Site

City

Poznan

ZIP/Postal Code

60-693

Country

Poland

Facility Name

Novartis Investigative Site

City

Rzeszow

ZIP/Postal Code

35-021

Country

Poland

Facility Name

Novartis Investigative Site

City

Warszawa

ZIP/Postal Code

02 781

Country

Poland

Facility Name

Novartis Investigative Site

City

Lisboa

ZIP/Postal Code

1769-001

Country

Portugal

Facility Name

Novartis Investigative Site

City

Matosinhos

ZIP/Postal Code

4454 513

Country

Portugal

Facility Name

Novartis Investigative Site

City

Porto

ZIP/Postal Code

4100-180

Country

Portugal

Facility Name

Novartis Investigative Site

City

Floresti

State/Province

Cluj

ZIP/Postal Code

407280

Country

Romania

Facility Name

Novartis Investigative Site

City

Bucuresti

ZIP/Postal Code

010991

Country

Romania

Facility Name

Novartis Investigative Site

City

Cluj-Napoca

ZIP/Postal Code

400124

Country

Romania

Facility Name

Novartis Investigative Site

City

Iasi

ZIP/Postal Code

700483

Country

Romania

Facility Name

Novartis Investigative Site

City

Arkhangelsk

ZIP/Postal Code

163045

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

Kaliningrad

ZIP/Postal Code

236006

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

Moscow

ZIP/Postal Code

143423

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

Obninsk

ZIP/Postal Code

249036

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

Omsk

ZIP/Postal Code

644013

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

Pushkin Saint Petersburg

ZIP/Postal Code

196603

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

Ryazan

ZIP/Postal Code

390011

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

Saint Petersburg

ZIP/Postal Code

197022

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

St Petersburg

ZIP/Postal Code

192148

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

St Petersburg

ZIP/Postal Code

197758

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

Yaroslavl

ZIP/Postal Code

150054

Country

Russian Federation

Facility Name

Novartis Investigative Site

City

Ljubljana

ZIP/Postal Code

1000

Country

Slovenia

Facility Name

Novartis Investigative Site

City

Cordoba

State/Province

Andalucia

ZIP/Postal Code

14004

Country

Spain

Facility Name

Novartis Investigative Site

City

Sevilla

State/Province

Andalucia

ZIP/Postal Code

41013

Country

Spain

Facility Name

Novartis Investigative Site

City

Santander

State/Province

Cantabria

ZIP/Postal Code

39008

Country

Spain

Facility Name

Novartis Investigative Site

City

Badalona

State/Province

Catalunya

ZIP/Postal Code

08916

Country

Spain

Facility Name

Novartis Investigative Site

City

Barcelona

State/Province

Catalunya

ZIP/Postal Code

08036

Country

Spain

Facility Name

Novartis Investigative Site

City

Hospitalet de LLobregat

State/Province

Catalunya

ZIP/Postal Code

08907

Country

Spain

Facility Name

Novartis Investigative Site

City

Valencia

State/Province

Comunidad Valenciana

ZIP/Postal Code

46010

Country

Spain

Facility Name

Novartis Investigative Site

City

Santiago de Compostela

State/Province

Galicia

ZIP/Postal Code

15706

Country

Spain

Facility Name

Novartis Investigative Site

City

La Laguna

State/Province

Santa Cruz De Tenerife

ZIP/Postal Code

38320

Country

Spain

Facility Name

Novartis Investigative Site

City

Madrid

ZIP/Postal Code

28006

Country

Spain

Facility Name

Novartis Investigative Site

City

Madrid

ZIP/Postal Code

28009

Country

Spain

Facility Name

Novartis Investigative Site

City

Madrid

ZIP/Postal Code

28041

Country

Spain

Facility Name

Novartis Investigative Site

City

Bern

ZIP/Postal Code

3010

Country

Switzerland

Facility Name

Novartis Investigative Site

City

Fribourg

ZIP/Postal Code

1708

Country

Switzerland

Facility Name

Novartis Investigative Site

City

Geneve 14

ZIP/Postal Code

CH 1211

Country

Switzerland

Facility Name

Novartis Investigative Site

City

Taichung

State/Province

Taiwan ROC

ZIP/Postal Code

40201

Country

Taiwan

Facility Name

Novartis Investigative Site

City

Changhua

ZIP/Postal Code

50006

Country

Taiwan

Facility Name

Novartis Investigative Site

City

Hualien

ZIP/Postal Code

970

Country

Taiwan

Facility Name

Novartis Investigative Site

City

Kaohsiung City

ZIP/Postal Code

83301

Country

Taiwan

Facility Name

Novartis Investigative Site

City

Kaohsiung

ZIP/Postal Code

82445

Country

Taiwan

Facility Name

Novartis Investigative Site

City

Taichung

ZIP/Postal Code

40447

Country

Taiwan

Facility Name

Novartis Investigative Site

City

Taichung

ZIP/Postal Code

40705

Country

Taiwan

Facility Name

Novartis Investigative Site

City

Taipei

ZIP/Postal Code

10002

Country

Taiwan

Facility Name

Novartis Investigative Site

City

Taipei

ZIP/Postal Code

11217

Country

Taiwan

Facility Name

Novartis Investigative Site

City

Taoyuan

ZIP/Postal Code

33305

Country

Taiwan

Facility Name

Novartis Investigative Site

City

Songkhla

State/Province

Hat Yai

ZIP/Postal Code

90110

Country

Thailand

Facility Name

Novartis Investigative Site

City

Khon Kaen

State/Province

THA

ZIP/Postal Code

40002

Country

Thailand

Facility Name

Novartis Investigative Site

City

Bangkok

ZIP/Postal Code

10300

Country

Thailand

Facility Name

Novartis Investigative Site

City

Bangkok

ZIP/Postal Code

10330

Country

Thailand

Facility Name

Novartis Investigative Site

City

Bangkok

ZIP/Postal Code

10400

Country

Thailand

Facility Name

Novartis Investigative Site

City

Bangkok

ZIP/Postal Code

10700

Country

Thailand

Facility Name

Novartis Investigative Site

City

Chaingmai

ZIP/Postal Code

50200

Country

Thailand

Facility Name

Novartis Investigative Site

City

Ankara

State/Province

Yenimahalle

ZIP/Postal Code

06200

Country

Turkey

Facility Name

Novartis Investigative Site

City

Adana

ZIP/Postal Code

01250

Country

Turkey

Facility Name

Novartis Investigative Site

City

Istanbul

ZIP/Postal Code

34303

Country

Turkey

Facility Name

Novartis Investigative Site

City

Izmir

Country

Turkey

Facility Name

Novartis Investigative Site

City

Pendik / Istanbul

ZIP/Postal Code

34899

Country

Turkey

Facility Name

Novartis Investigative Site

City

Cambridge

State/Province

Cambrigdeshire

ZIP/Postal Code

CB2 0QQ

Country

United Kingdom

Facility Name

Novartis Investigative Site

City

Truro

State/Province

Cornwall

ZIP/Postal Code

TR1 3LJ

Country

United Kingdom

Facility Name

Novartis Investigative Site

City

Cheltenham

State/Province

Gloucestershire

ZIP/Postal Code

GL53 7AN

Country

United Kingdom

Facility Name

Novartis Investigative Site

City

Wirral

State/Province

Merseyside

ZIP/Postal Code

CH63 4JY

Country

United Kingdom

Facility Name

Novartis Investigative Site

City

Ipswich

State/Province

Suffolk

ZIP/Postal Code

IP4 5PD

Country

United Kingdom

Facility Name

Novartis Investigative Site

City

Guildford

State/Province

Surrey

ZIP/Postal Code

GU2 7XX

Country

United Kingdom

Facility Name

Novartis Investigative Site

City

Birmingham

ZIP/Postal Code

B9 5SS

Country

United Kingdom

Facility Name

Novartis Investigative Site

City

Bristol

ZIP/Postal Code

BS2 8HN

Country

United Kingdom

Facility Name

Novartis Investigative Site

City

Leicester

ZIP/Postal Code

LE1 5WW

Country

United Kingdom

Facility Name

Novartis Investigative Site

City

London

ZIP/Postal Code

EC14 7BE

Country

United Kingdom

Facility Name

Novartis Investigative Site

City

London

ZIP/Postal Code

NW3 2QG

Country

United Kingdom

Facility Name

Novartis Investigative Site

City

Nottingham

ZIP/Postal Code

NG5 1PB

Country

United Kingdom

Facility Name

Novartis Investigative Site

City

Oxford

ZIP/Postal Code

OX3 7LJ

Country

United Kingdom

Facility Name

Novartis Investigative Site

City

Preston

ZIP/Postal Code

PR2 9HT

Country

United Kingdom

Facility Name

Novartis Investigative Site

City

Stoke-on-Trent

ZIP/Postal Code

ST4 6QG

Country

United Kingdom

Facility Name

Novartis Investigative Site

City

Hanoi

ZIP/Postal Code

100000

Country

Vietnam

12. IPD Sharing Statement

Plan to Share IPD

Yes

IPD Sharing Plan Description

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data will be available according to the process described on www.clinicalstudydatarequest.com.

Learn more about this trial

We'll reach out to this number within 24 hrs